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Persistent infection of murine astrocytoma (DBT) cells with mouse hepatitis virus (MHV) has been estab-
lished. From this in vitro virus-host system, persistence is mediated at the level of cellular MHV receptor
(MHVR) expression and increased virus virulence. MHV persistence selects for resistant host cell populations
which abate virus replication. Reductions in MHVR expression were significantly associated with increased
host resistance, and transfection of MHVR into resistant host cells completely restored the capacity of cells to
support efficient replication of MHV strain A59. The emergence of resistant host cells coselected for variant
viruses that had increased avidity for MHVR and also recognized different receptors for entry into resistant
cells. These data illustrate that MHV persistence in vitro provides a model to identify critical sites of virus-host
interaction at the cellular level which are altered during the evolution of host cell resistance to viral infection
and the coevolution of virus virulence.
The mechanisms by which highly cytolytic RNA viruses es-
tablish and maintain a persistent infection in cell culture are
not completely understood but likely involve the evolution of
the host cell and the virus to ensure dual survival (2, 15). While
down regulation of viral gene function and expression has been
proposed as the predominant mechanism by which RNA vi-
ruses limit cell killing (6, 32), coevolution of the host cell and
the virus has been demonstrated to function in the establishment
and maintenance of foot-and-mouth disease virus (FMDV), po-
liovirus, reovirus, and parvovirus persistence. In these models
persistence selects for resistant host cells which block virus
infection or cytopathic effects, subsequently selecting for co-
evolving variant viruses which replicate efficiently in these cells
(6, 41, 50). Unfortunately, the mechanisms of host cell resis-
tance, subsequent virus adaptation, and coevolution in culture
and their roles in persistence are poorly understood.
Mouse hepatitis virus strain A59 (MHV-A59), a member of
the family Coronaviridae, contains a 32-kb single-stranded pos-
itive-polarity RNA genome (47). MHV entry into susceptible
cells is mediated by specific interactions between the viral S
glycoprotein and the cellular MHV receptor (MHVR) (18, 19).
MHVR is a 110-kDa member of the biliary glycoprotein (BGP)
subgroup of the carcinoembryonic antigen (CEA)-related glyco-
protein (CGM) family in the immunoglobulin superfamily (18,
42). Two Bgp genes (Bgp1 and Bgp2) have been characterized
(42, 45). Two polymorphic alleles, Bgp1a and Bgp1b of the Bgp1
gene encode numerous glycoprotein isoforms that are ex-
pressed from alternative splicing of a single gene and can serve
as receptors for MHV (45). Bgp A, formerly designated
mmCGM1 or MHVR1, is one of the Bgp1a gene products and
is expressed in BALB/c, C57BL/6, and C3H mice (17). Bgp B,
formerly designated mmCGM2 or MHVR2, is one of the
Bgp1b products and is expressed in resistant SJL/J and outbred
CD1 mice (17, 42, 70). BGPs may be expressed as two or four
immunoglobulin C (IgC)-like intracellular domains with long
or short intracytoplasmic tails. The N-terminal domains of
BGPs interact with the MHV S glycoprotein to initiate infec-
tion (16, 17). Both two- and four-domain isoforms of Bgp A
can serve as functional receptors for MHV-A59 (17, 70). Al-
though Bgp B is also a functional MHV receptor, it binds virus
less efficiently than the Bgp A isoforms as determined by virus
overlay protein blot assays in vitro (17, 67). A novel Bgp gene,
Bgp2, whose product can also serve as a receptor for MHV,
although it is not as efficient as Bgp A, has been recently
identified (45).
The precise mechanisms regulating MHV persistence are
unclear (4, 23, 37, 60). Persistently infected cultures produce
defective interfering RNAs and temperature-sensitive, fusion-
defective, and small-plaque variant viruses, but these mutants
are probably not critical for establishing MHV persistence (28,
30, 34, 61). Intraleader mutations and open reading frames as
well as leader RNA polymorphisms which may attenuate virus
gene expression, transcription, and replication evolve during
the maintenance of bovine coronavirus persistence in vitro
(32). We have shown that MHV persistence in vitro selects for
more-virulent variant viruses containing a mutation in the
genomic 59 untranslated region (59-UTR) which enhances ex-
pression of the MHV polymerase gene products (10). Other
studies suggest that alterations in host gene expression are
critical and that the epigenetic expression of the Bgp A recep-
tor may contribute to host cell resistance and MHV persistence
(54). In this study, we demonstrated that MHV persistence in
vitro is mediated by the epigenetic selection for resistant host
cells which express little if any Bgp A protein. In addition,
MHV persistence also requires the subsequent coevolution of
variant viruses which display altered avidity for Bgp A and
recognize an entirely new receptor protein(s) for entry into
these resistant cells. Thus, this in vitro model has shown that
MHV persistence is mediated by resistance to infection at the
cellular level and results in coevolution of variant viruses with
increased virulence and replication efficiency.
MATERIALS AND METHODS
Viruses and cells. DBT cells were originally established from a delayed brain
tumor (DBT) in a CDF1 mouse inoculated intracerebrally with the Schmidt-
Ruppin strain of Rous sarcoma virus (29, 38). DBT cells were obtained from
Shinji Makino (University of Texas at Austin) and were maintained within 10
passages of this progenitor stock. DBT cells were maintained in Eagle minimum
essential medium containing 5% fetal calf serum and 3% newborn calf serum




and supplemented with 5% tryptose phosphate broth and 1% gentamicin and
kanamycin. Baby hamster kidney (BHK) cells were kindly provided by Robert E.
Johnson (University of North Carolina at Chapel Hill) and maintained in alpha
minimum essential medium supplemented with 7% fetal calf serum, 10% tryp-
tose phosphate broth, and 1% penicillin and streptomycin. BHK cell lines ex-
pressing the Bgp A receptor (BHK-MHVR cells) or the Bgp B receptor (BHK-
mmCGM2 cells) were kindly provided by Kathryn V. Holmes (University of
Colorado Health Sciences Center). These cell lines were grown in alpha mini-
mum essential medium containing 10% fetal calf serum, 10% tryptose phosphate
broth, 1% penicillin and streptomycin, and 800 mg of Geneticin (G418-sulfate)
(Sigma) per ml. MHV-A59 was propagated and plaqued in DBT cells as previ-
ously described (56). Variant viruses from DBT cultures persistently infected
with MHV-A59 were collected at 119 days postinfection and plaque purified
twice in DBT cells as previously described (10), and they either contain the
A-to-G mutation at the nucleotide (nt) 77 locus in the 59-UTR (V131 to V161)
or are identical to MHV-A59 (V12 and V42) (10).
Uninfected DBT cells and persistently infected DBT cells at 30 days postin-
fection were grown in six-well plates at ca. five cells per well. Individual clones
were independently isolated and subcloned twice by this technique. Sixteen cell
clones (designated DBT 1 to DBT 16) were isolated from uninfected DBT cells
and 18 clones (designated PDBT 1 to PDBT 18) were isolated from persistently
infected cultures at 30 days postinfection.
Virus growth curves, detection of intracellular viral RNA, and virus virulence
assays. Individual cell clones were seeded at densities of 2 3 105 cells per well
in 24-well plates and infected with MHV-A59 or different variant viruses at a
multiplicity of infection (MOI) of 5 for 1 h at room temperature. The inoculum
was removed, the monolayers were washed twice with phosphate-buffered saline
(PBS), and fresh medium was added. Samples of virus were harvested at different
times postinfection and stored at2708C for plaque assay. Intracellular RNA was
extracted at different times postinfection by using RNA STAT-60 reagents (total
RNA/mRNA isolation reagent; Tel-TEST ‘‘B,’’ Inc., Friedwood, Tex.). Equiva-
lent amounts of intracellular RNA were bound to nitrocellulose filters, pre-
washed and prehybridized as previously described, and hybridized with a radio-
labeled 1.6-kb MHV-A59 N gene probe from the IBI 76N cDNA clone (56). The
32P-radiolabeled DNA probe was synthesized by using a random primer DNA
labeling system (GIBCO, BRL).
The susceptibilities of different cell clones to killing by MHV-A59 and differ-
ent variant viruses were determined by using a modified virulence assay devel-
oped for FMDV (41). About 2 3 106 cells were seeded onto 60-mm-diameter
dishes in triplicate and infected with wild-type MHV-A59 or variant viruses at an
MOI of 5. Under these conditions, extensive cytopathology was evident in the
parental DBT cells after 16 to 24 h of wild-type MHV-A59 infection. At 24 h
postinfection, medium was removed from the infected cultures, and the remain-
ing cells were trypsinized and washed twice with PBS. After centrifugation, the
cells were resuspended in PBS containing trypan blue stain. The number of
viable cells, as determined by dye exclusion, was counted directly under a grid
and compared with the number of cells in uninfected controls.
Detection of viral antigens by immunofluorescence. Different cell clones
grown on LabTek chamber slides (Nunc, Inc., Naperville, Ill.) were infected with
MHV-A59 or the V161 or V12 variant virus at an MOI of 5 for 1 h at room
temperature. The inoculum was removed, the cells were washed twice with PBS,
and complete medium was added to the cultures. At different times postinfec-
tion, infected cells were fixed with acetone-methanol (1:1) and stored at 48C.
Fixed cells were incubated with a 1:200 dilution of a polyclonal antibody against
MHV3 (kindly provided by Jean-Pierre Martin, Louis Pasteur University, Stras-
bourg, France) for 30 min at room temperature. After three washes with PBS,
the cells were incubated with 1:100 dilution of goat anti-mouse IgG–fluorescein
isothiocyanate conjugate (Sigma) for 30 min at room temperature, washed with
PBS, and examined under a Nikon FXA fluorescence microscope.
Detection of Bgp A by FACS analysis. The expression of Bgp A was assessed
by fluorescence-activated cell sorter (FACS) analysis using the conventional
second-antibody indirect-staining method according to the procedures provided
by the manufacturer (Becton Dickinson Immunocytometry Systems, San Jose, Ca-
lif.). Briefly, 106 cells were harvested by trypsinization, resuspended in PBS, and
incubated with a 1:5 dilution of monoclonal antibody (MAb) CC1 (kindly pro-
vided by Kathryn V. Holmes, University of Colorado Health Sciences Center),
which recognizes the N-terminal domain of Bgp A. After 45 min on ice, the cells
were washed twice with cold PBS and incubated with either a 1:30 dilution of a
sheep anti-mouse IgG R–phycoerythrin conjugate (Sigma) or a 1:25 dilution of
a goat anti-mouse IgG–fluorescein isothiocyanate isomer conjugate (Sigma) for
45 min on ice. Following two washes with cold PBS, the cells were resuspended
at a concentration of 23 106 cells per ml in 0.5 ml and analyzed with a FACScan
equipped with CICERO Interface and IBM-based Cyclops Software (Becton
Dickinson Immunocytometry Systems).
Stable expression of Bgp A in cell lines. The plasmid MHVR, containing the
four-domain isoform of Bgp1a under the control of the cytomegalovirus pro-
moter in the pcDNA3 vector (Invitrogen), was kindly provided by Kathryn V.
Holmes (University of Colorado Health Sciences Center) and used for stable
expression of Bgp A. MHVR was transfected into an MHV-A59-resistant cell
clone (PDBT 5) isolated from persistently infected DBT cells at 30 days postin-
fection. Transfection was performed with 20 mg of the plasmid and 5 3 106 cells
by the CaPO4 DNA transfection method with the transfection MBS mammalian
transfection kit (Stratagene) according to the manufacturer’s recommendations.
Individual neomycin-resistant clones were isolated after 4 weeks of G418 selec-
tion, and clones expressing Bgp A were identified by FACS analysis.
Preparation of cellular RNA and reverse transcriptase PCR (RT-PCR) am-
plification. Total cellular RNA was prepared from different cloned cell lines by
using RNA STAT-60 reagents (total RNA/mRNA isolation reagent) according
to the manufacturer’s direction (Tel-TEST ‘‘B’’, Inc.). To detect Bgp1 mRNA
expression, 5 mg of total RNA was reverse transcribed with avian myeloblastosis
virus reverse transcriptase (Promega) as previously described (55) with primer
R1440(1) (TAG GAG AGT TGT CAG AAG), which is complementary to nt
1440 to 1458 at the 39 end of the Bgp1 gene in the intracytoplasmic tail domain
(18, 42). The cDNA was amplified by PCR with the 59 end primer R436(1)
(GAT ATG ACA GAT GAA AAC TAT) (nt 436 to 453), which is in the
A2a/A2b domain of Bgp1, or R1073(1) (CAG TCA AAG AAC TAG ACT) (nt
1073 to 1090), located in the N1/N2 domain of Bgp1 (18, 42), and the 39 end
primer R1440(2) (see Fig. 5A). PCR was performed with Taq DNA polymerase
(GIBCO, BRL) for 30 cycles at 948C for 1.5 min, 458C for 1.5 min, and 728C for
2 min. Contamination of the RNA preparations by residual genomic DNA was
detected by direct amplification with Taq polymerase under the same conditions.
Southern blot analysis of RT-PCR products. The PCR products were sepa-
rated by electrophoresis in 1.2% agarose gels and then transferred to a Hy-
bond-N1 membrane (Amersham) according to the manufacturer’s directions.
The membrane was prehybridized at 428C overnight in a buffer containing 0.9 M
NaCl, 0.09 M sodium citrate, 13Denhardt’s solution (containing 0.2 mg of Ficoll
per ml, 0.2 mg of polyvinylpyrrolidine per ml, and 0.2 mg of bovine serum
albumin per ml), 0.5% sodium dodecyl sulfate (SDS), 100 mg of salmon sperm
DNA per ml, and 0.05% sodium PPi. To detect Bgp1 expression, a 32P-labeled
specific Bgp1 internal oligonucleotide probe, R1182(1) (CTC TCC CAG AAC
AAC AGC ATC) (nt 1182 to 1203), located in the A2a/A2b domain and con-
served in all Bgp1a and Bgp1b isoforms (18, 42), was hybridized with the filter at
428C for 18 h. After hybridization, the membrane was washed with 23 SSC (13
SSC is 0.15 M NaCl plus 0.015 M sodium citrate) containing 0.1% SDS at room
temperature twice for 10 min each, then with 13 SSC containing 0.1% SDS at
428C twice for 15 min each, and then with 0.13 SSC containing 0.1% SDS at
428C twice for 15 min each.
Blockade of Bgp A receptor. Different cell clones were seeded at densities of
23 105 cells per well in 24-well plates and incubated with 200 ml of a 1:2 dilution
of anti-Bgp A MAb CC1 for 1 h at 378C. The MAb was collected hybridoma
culture supernatants and was kindly provided by Kathryn V. Holmes (University
of Colorado Health Sciences Center). After the incubation, the antibodies were
removed and the cells were challenged with MHV-A59 or variant viruses at an
MOI of 5 for 1 h at room temperature. The virus inoculate was then removed, the
cultures were washed twice with PBS to remove residual virus, and 300 ml of a 1:2
mixture of MAb CC1 and complete medium was added to the cultures. Samples
were harvested at different times postinfection and stored at 2708C for plaque
assay in DBT cells. As a control, the cells were pretreated with an equivalent
amount of a MAb with the same IgG isotype as MAb CC1 but directed against
an irrelevant antigen (anti-E2 glycoprotein of Sindbis virus, kindly provided by
Robert E. Johnson, University of North Carolina at Chapel Hill).
Statistical analysis. Statistical significance was determined by Student’s t test
or by the one- or two-tailed Fisher exact test (51).
RESULTS
MHV persistence selects for DBT cells which resist wild-
type virus infection. Acute MHV-A59 infection in DBT cells
was characterized by extensive fusion and death of approxi-
mately 95% of the cells within 24 h. Surviving cells replicated
to confluence over the next 2 to 3 days, and progressively
decreasing levels of virus-induced cytopathic effects and fusion
were evident as the cells were passaged over the next 119 days.
Virus titers approached 106 PFU/ml, and about 20 to 30% of
the cells displayed viral antigen at 30 days postinfection (data
not shown) (34). Over time, the percentage of antigen-positive
cells also declined, until about 10% were positive by 119 days
postinfection. To study the evolution of the surviving cell pop-
ulation, we cloned 16 DBT cell lines (DBT 1 to 16) from
uninfected laboratory stock cell cultures and 18 persistent cell
clones (PDBT 1 to 18) from persistently infected DBT cultures
at 30 days postinfection. Epigenetic variability was clearly ev-
ident in our laboratory stock of DBT cells, since MHV-A59
infection in 81% of the DBT clones resulted in extensive cy-
topathic effects, syncytium formation, and cell death. In con-
trast, about 19% of the DBT cell clones (DBT 3, 7, and 8)
produced little syncytium formation following MHV-A59 in-
fection (data not shown). To determine whether the DBT cell
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clones were permissive for MHV-A59 infection, virus growth
curves were determined with both fusion-positive (DBT 9, 14,
and 16) and fusion-negative (DBT 3, 7, and 8) cell clones (Fig.
1A). The average yields of MHV-A59 in these six DBT clones
were 6.7 6 4.4 PFU per cell at 24 h postinfection. MHV-A59
infection in fusion-positive clones resulted in virus yields of 6
to 14 PFU per cell. Although wild-type virus yields were re-
duced, productive infection was also detected in the fusion-
negative clones, in which the virus yields ranged from 1.5 to 7.3
PFU per cell.
Surprisingly, all 18 persistent cell clones isolated at 30 days
postinfection had cured virus infection, as no infectious virus,
viral RNA, or viral protein was detected. MHV-A59 infection
in all 18 persistent cell clones was associated with little if any
cytopathology or syncytium formation (data not shown).
MHV-A59 growth curves were evaluated in more detail with
six persistent cell clones (PDBT 2, 3, 5, 6, 7, and 11). Statisti-
cally significant reductions in MHV-A59 replication were
clearly evident in the PDBT cell clones compared with the
DBT clones (Fig. 1B). Virus yields ranged from 0.02 to 1.3
PFU per cell in these six clones, with mean virus yields per cell
of 0.39 6 0.47 PFU (P , 0.01). MHV-A59 replication was
almost completely inhibited in PDBT 5 and PDBT 11, since
virus yields averaged 0.02 to 0.08 PFU per cell (Fig. 1B). These
data clearly indicated that MHV persistence was associated
with the evolution of host cells which resisted MHV-A59 in-
fection and cytopathic effects in vitro.
More-virulent MHV-A59 variant viruses coevolve during
persistent infection. Previous studies suggested that the selec-
tion for host cells that resisted wild-type virus infection was
associated with the coevolution of more-virulent virus variants
during persistence in vitro (41). We have shown that MHV
persistence in vitro is associated with the evolution of a specific
mutation in the 59-UTR of the genomic RNA which enhances
the replication efficiency of MHV variants isolated at 119 days
postinfection (10). Therefore, we examined the replication ef-
ficiencies and virulence of variant viruses, isolated at 119 days
postinfection, which contained the 59-UTR mutation (V131 to
V161) or lacked the mutation at this locus (V12 and V42) in
DBT and PDBT cell clones.
The replication of variant virus V161 was extremely efficient
and elicited extensive syncytium formation in all DBT cell
clones, including those DBT clones that resisted wild-type
MHV-A59-induced fusion and cytopathology (DBT 3, 7, and
8) (Fig. 1A). The mean yields of V161 in the DBT cell clones
approached 52.4 6 27.4 PFU per cell, which was significantly
higher than those detected in the same DBT cell clones in-
fected with the parental MHV-A59 virus (6.7 6 4.4) (P ,
0.001). Similar results were also obtained with the V12 virus
(data not shown). Viral cytopathology and cell killing assays
also demonstrated that the V12 and V161 variant viruses were
more cytolytic than MHV-A59. For example, fewer than 1% of
DBT 9 cells survived V12 or V161 infection, compared with
4.2% cell survivors following parental MHV-A59 infection (P
, 0.01) (Table 1). Other variant viruses (V42, V131, V141,
and V151) isolated at 119 days postinfection also displayed
increases in virulence and viral replication similar to those
shown by V12 and V161 in DBT 9 cells (Table 1). These data
strongly imply that variant viruses which were more virulent
and replicated more efficiently in DBT cells cloned from our
original laboratory stock have emerged by 119 days postinfec-
tion.
We next examined the replication efficiencies and virulence
of these variant viruses in PDBT cell clones isolated at 30 days
postinfection. Although all persistent cell clones were permis-
sive for V161 virus replication, viral yields were reduced three-
to fourfold compared with the maximal yields detected in DBT
cell clones (P , 0.05) (Fig. 1B and Table 1). In PDBT clones,
V161 virus replication was also more efficient than parental
virus replication, since the yields of V161 and the parental
MHV-A59 averaged 13.9 6 10.2 and 0.39 6 0.47 PFU per cell,
respectively (P , 0.01). To determine whether this phenotype
was characteristic of other variant viruses isolated at 119 days
postinfection, the replication efficiencies of five additional vari-
ant viruses, containing the 59-UTR mutation (V131, V141,
and V151) or containing the wild-type sequence at this locus
(V12 and V42), were examined in DBT 9 and PDBT 5 cells.
All variant viruses replicated to significantly higher titers than
the parental MHV-A59 in both cell clones (Table 1) (P ,
0.001). In addition, the replication of these viruses in DBT cells
was also more efficient than that in PDBT clones (P , 0.05).
To determine whether the variant viruses were more virulent
than MHV-A59 in persistent cell clones, PDBT 5 cells were
infected with MHV-A59, V12, or V161. At 24 h postinfection,
more than 95% of the PDBT 5 cells had survived MHV-A59
infection. Under identical conditions, only 66 and 69% of the
PDBT 5 cells had survived V12 and V161 infection, respec-
tively (Table 1). Immunofluorescence assays at 7 h postinfec-
tion indicated that MHV-A59 infected fewer than 1% of
PDBT 5 cells, compared with 15 to 20% for V12- or V161-
infected cultures (Fig. 2B and C).
Since replication of wild-type MHV-A59 was dramatically
reduced in the PDBT clones, we next determined whether the
reduction in virus yields occurred prior to or after virus tran-
scription. Cultures of PDBT 5 cells were infected with MHV-
A59, and intracellular RNA was isolated at different times
postinfection, bound to nitrocellulose filters, and probed with
an MHV-A59 N gene cDNA probe (56). Significant amounts
of viral RNA synthesis were detected in MHV-A59-infected
DBT 9 cells but not in the MHV-A59-infected PDBT 5 cells,
suggesting that the replication of MHV-A59 was inhibited at
an early stage prior to RNA synthesis (Fig. 3). Immunofluo-
rescence assays also confirmed this observation (Fig. 2B and
C). These data were consistent with the hypothesis that more-
virulent variant viruses had evolved during MHV persistence
in vitro which could overcome the early block of MHV-A59
infection exhibited by persistent cell clones.
Host cell resistance is associated with reductions in Bgp1
expression. Although selection for host cells that resist viral
infection during MHV, reovirus, poliovirus, and FMDV per-
sistence has been reported, their role in persistence has not
been elucidated, and the genetic basis for host cell resistance is
not clear (6, 15, 41, 54). Since our data had suggested that
resistance to MHV-A59 infection in PDBT cell clones oc-
curred at a early step in the virus replication cycle, and since
previous studies also suggested that Bgp A (MHVR) expres-
sion was reduced during MHV persistence in 17CL-1 cells
(54), the levels of Bgp1 expression in the cloned cell lines were
examined. The relative levels of Bgp1 mRNA and protein ex-
pression in DBT and PDBT cell clones were quantitated by
RT-PCR and by FACS analysis with MAb CC1, which recog-
nizes the N-terminal domains of both the two- and four-do-
main isoforms of Bgp A. As expected, over 77% of the DBT 9
cells were Bgp A positive by FACS analysis, with a mean
fluorescence of 6.62 after subtraction of background fluores-
cence (Fig. 4A). In contrast, the mean fluorescence of PDBT 5
was only 0.26, and it was almost equivalent to that of unstained
control cells (Fig. 4E). Since these data suggested that the
absence of Bgp A may contribute to the resistance to wild-type
MHV-A59 infection, we compared the expression of Bgp A in
six additional cell clones. DBT 8 (fusion negative) and DBT 14
(fusion positive) were permissive for MHV-A59 infection (Fig.
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FIG. 1. Growth of MHV-A59 and V161 in DBT and PDBT cell clones. Individual clones of DBT cells (A) or PDBT cells (B) were isolated as described in Materials
and Methods. Cultures (2 3 105 cells) of cloned DBT or PDBT cells were infected with parental or variant viruses at an MOI of 5. Virus samples were collected at
different times postinfection, and titers were determined on DBT cells by plaque assay.
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1). Both cell clones clearly expressed high levels of Bgp A
compared with an unstained control (Fig. 4B and C), with a
mean fluorescence of 4.14 and 11.60, respectively. It was inter-
esting that the expression of Bgp A in fusion-negative clone 8
was lower than that detected in fusion-positive clones (DBT 9
and DBT 14). In contrast to the DBT cell clones which ex-
pressed high levels of the receptor, all PDBT clones examined
were Bgp A negative by FACS analysis, with mean fluores-
FIG. 1—Continued.
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cences of 1.01, 0.32, 0.10, and 0.83 in PDBT clones 3, 2, 7, and
11, respectively (Fig. 4E to I). After adjustment for back-
ground staining levels, an approximate 10- to 20-fold decrease
in Bgp A expression was evident in persistent cell clones com-
pared with DBT cell clones.
To confirm the reduction in Bgp A expression in these cell
clones, levels of Bgp1 mRNA were detected by using RT-PCR,
a more sensitive technique (53). Intracellular RNA was isolated
from DBT and PDBT cell clones, and cDNA was synthesized by
using a Bgp-specific oligonucleotide primer, 1440(2), as de-
scribed in Materials and Methods. Two specific sets of primer
pairs, (i) 436(1) and 1440(2) and (ii) 1073(1) and 1440(2),
spanning nt 436 to 1140 and nt 1073 to 1440 in Bgp A, respec-
tively, were used for PCR amplification (Fig. 5A) (18, 42). The
products were separated on agarose gels, bound to nitrocellu-
lose filters, and probed with a 32P-labeled specific internal
primer, 1182(1) (nt 1182 to 1203 in Bgp A) (Fig. 5A) (18, 42).
With the 1073(1) and 1440(2) primers, which reside within
the A2a/A2b domain and intracytoplasmic tails, respectively,
all Bgp1a and Bgp1b isoforms will result in a 370-bp product
following PCR amplification (Fig. 5A). In contrast, with the
436(1) and 1440(2) primer pair, four-domain isoforms of
Bgp1a or Bgp1b will result in an ;1.0-kb PCR product, while
two-domain isoforms will result in a 440-bp product (42). By
RT-PCR, expression of BGP mRNA was clearly evident in all
DBT cell clones (DBT 8, 9, and 14), consistent with our FACS
results. Interestingly, the two-domain isoforms of BGP were
predominantly expressed in DBT cell clones, since the 440-bp
product was preferentially detected in these gels (Fig. 5B, lanes
1). In the absence of reverse transcription, no BGP products
were detected following Taq amplification, ruling out the pos-
sibility of genomic DNA contamination in our mRNA prepa-
rations (data not shown). Importantly, no significant levels of
Bgp1 mRNA expression were detected in persistent cell clones
(PDBT 2, 3, 5, 7, and 11) (Fig. 5B), consistent with previous
findings that MHV-A59 persistence in vitro selected for host
cell populations that expressed little if any Bgp1a or Bgp1b
FIG. 2. MHV-A59, V161, or V12 viral protein expression in different cell clones. Cultures of cells were infected with MHV-A59, V161, or V12 and fixed as
described in Materials and Methods at different times postinfection. Viral antigen expression was detected by immunofluorescence assay with anti-MHV polyclonal
serum. (A and B) MHV-A59 infection in DBT 9 (A) or PDBT 5 (B) cells at 7 h postinfection. (C) V161 infection in PDBT 5 cells at 7 h postinfection. (D to F)
MHV-A59 (D), V161 (E), and V12 (F) viral antigen detected at 24 h postinfection in DBT 9 cells pretreated with MAb CC1.
TABLE 1. Virulence and yields of MHV-A59 and variant viruses in
DBT 9 and PDBT 5 cell clones at 24 h postinfection
Virus
% Cell survival (mean 6 SD) Virus yield (PFU/cell)
DBT 9 PDBT 5 DBT 9 PDBT 5
A59 4.20 6 0.35 94.7 6 1.4 14.3 0.02
V161 0.20 6 0.15 68.7 6 2.5 36.7 10.00
V42 0.80 6 0.17 NDa 39.0 10.00
V12 0.30 6 0.06 66.3 6 3.0 33.0 11.30
V131 0.25 6 0.07 ND 58.0 14.70
V141 0.53 6 0.12 ND 26.0 15.80
V151 0.73 6 0.11 ND 32.0 15.00
a ND, not determined.
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products. Statistical analysis also confirmed that significant dif-
ferences in Bgp1 expression between the populations of PDBT
and DBT cell clones were evident (P , 0.05). These data
argued that MHV infection eliminated BGP-expressing cell
populations during acute infection and selected for BGP-neg-
ative cells that could survive and proliferate in the presence of
virus.
Mechanisms of cell resistance to MHV-A59 infection. To
confirm the hypothesis that persistent cell clones resisted
MHV-A59 infection by reducing or abating BGP expression
(54), a plasmid expressing the four-domain Bgp A (MHVR)
under the control of a cytomegalovirus promoter in the
pcDNA3 vector was transfected into PDBT 5 cells to obtain
cell lines that stably express Bgp A (18). Following transfec-
tion, neomycin-resistant cell clones were isolated, and FACS
analysis with MAb CC1 was used to determine relative levels of
Bgp A expression. Several G418-resistant clones (designated
PDBT 5 R-1 to PDBT 5 R-24) were isolated, in which Bgp A
expression levels ranged from 4.97 to 429.39 (mean of fluores-
cence after removal of background). Since previous studies
with alphavirus have demonstrated that levels of receptor ex-
pression were critical elements in regulating virus-receptor in-
teraction and infectivity (65), all additional studies were per-
formed with the PDBT 5 R-14 clone, which expressed levels of
Bgp A similar to those of DBT cell clones. The PDBT 5 R-14
cells had a mean fluorescence of 4.97, compared with 0.26 in
the parental PDBT 5 cells and 6.62 in DBT 9 (Fig. 4D). The
PDBT 5 R-14 clone was clearly not an epigenetic variant ex-
isting within the PDBT 5 cell population, since RT-PCR anal-
ysis demonstrated that the four-domain isoform of Bgp A was
expressed after transfection of Bgp A, unlike the case for all
FIG. 3. Intracellular viral RNA detected in DBT 9 and PDBT 5 cell clones
infected with MHV-A59. Cells were infected with MHV-A59 at an MOI of 5, and
intracellular RNA was extracted at different times postinfection as described in
Materials and Methods. Equivalent amounts of intracellular RNA were bound to
nitrocellulose filters, and viral RNA was detected with a 32P-radiolabeled MHV-
A59 N gene probe. The dots were localized, excised, and counted after the filters
were exposed to Kodak X-ray film, and the amount of RNA is reported as counts
per minute.
FIG. 4. Expression of Bgp A in DBT and PDBT cell clones. Levels of Bgp A expression were analyzed by FACS after staining with MAb CC1 as described in
Materials and Methods. (A to C) Expression of Bgp A in DBT 9, 8, and 14, respectively; (E to I) expression of Bgp A in PDBT 5, 3, 2, 7, and 11, respectively; (D)
expression of Bgp A in PDBT 5 R-14.
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tested DBT cell clones (Fig. 5C). Following infection of PDBT
5 R-14 with the parental MHV-A59, high percentages of cells
(.80%) were antigen positive by immunofluorescence assay
and extensive syncytium formation (.70%) was observed in
the cultures. Replication of MHV-A59 was completely re-
stored and was nearly equivalent to levels of V161 and V12
variant virus replication in these cells at 24 h postinfection
(Fig. 6A). Significant levels of virus replication and syncytium
formation were also evident in all other PDBT 5 R clones that
expressed similar levels of Bgp A (data not shown). In contrast,
less than 1% of the MHV-A59-infected PDBT 5 cells were
viral antigen positive, and virus yields were 3 to 4 log units
lower. Importantly, a G418-resistant clone (PDBT 5 R-22),
which was Bgp A negative by FACS analysis, was as resistant as
its parental PDBT 5 clone to MHV-A59 infection (Fig. 6B). In
addition, MAb CC1 completely inhibited MHV-A59 but not
V161 and V12 replication in PDBT 5 R-14 cells (Fig. 6C).
These data clearly demonstrate that resistance in persistent
cell clones is mediated by low levels of BGP expression.
Mechanisms of increased variant virus virulence during
persistent infection. Findings in our laboratory and others
have demonstrated that MHV-A59 persistence in vitro was
associated with the emergence of host cells that resisted wild-
type virus infection by down regulation of BGP expression
(54). However, we have also shown that variant viruses which
replicate more efficiently in both sensitive and resistant cells
emerge during MHV persistence. Since Bgp A is either not
expressed or expressed at extremely low levels in the resistant
cells, it seems likely that the variant viruses contain mutations
which either confer an altered avidity for Bgp A or permit
recognition of an alternative receptor(s) for entry into these
cells. To test this hypothesis, we performed blockade experi-
ments to determine whether entry of MHV-A59 or variant
viruses could be abated by MAb CC1. Cultures of DBT 9 cells
were pretreated with MAb CC1 for 1 h, and then the antibod-
ies were removed and the cells were infected with MHV-A59,
V12, or V161 at an MOI of 5. The variant viruses V12 and
V161 replicated efficiently in DBT 9 cells either untreated or
pretreated with MAb CC1, yet the replication of MHV-A59
was completely blocked and was reduced by over 6 log units in
cells pretreated with MAb CC1 (Fig. 7A). Pretreatment with
antibodies reduced the replication of variant viruses by about 1
to 2 log units compared with that in the untreated controls and
reduced the number of infected DBT 9 cells from 99 to 52% as
detected by immunofluorescence. The detection of viral anti-
gens by immunofluorescence assay at 24 h postinfection also
confirmed a complete block in MHV-A59, but not in V12 or
V161, viral protein expression (Fig. 2A, D, E, and F). These
data suggest that the variant viruses must have increased avid-
ity for Bgp A, recognize different domains in Bgp A that are
not accessible to MAb CC1 blockade, and/or recognize a dif-
ferent receptor(s) for entry into resistant cell clones.
We next determined whether Bgp A (MHVR) functions as
a receptor for entry of the variant viruses. Previous studies
FIG. 5. Detection of Bgp1 mRNA in DBT and PDBT cell clones. Cellular RNA was isolated from individual cell clones, and RT-PCR was performed with
Bgp1-specific primers (A). The PCR products were detected by using a 32P-labeled Bgp1-specific internal oligonucleotide probe, 1182(1) (A). (B and C) Expression
of Bgp1 mRNA in DBT and PDBT cell clones (B) and PCR products detected in the PDBT 5 R-14 clone under identical experiment conditions (C). Lanes 1, cDNA
amplified with the 436(1) and 1440(2) primers; lanes 2, cDNA amplified with the 1073(1) and 1440(2) primers. p, other Bgp alleles detected in DBT cell clones but
not expressed in PDBT cell clones.
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have clearly established that MHV cannot replicate in BHK
cells unless these cells express Bgp A (18). BHK-MHVR cells,
which stably express Bgp A, were infected with MHV-A59,
V12, or V161. Although the MHV-A59, V12, and V161 vi-
ruses could not replicate in BHK cells (data not shown), they
replicated efficiently in BHK-MHVR cells, approaching titers
of 108 PFU/ml within 24 h. These data clearly demonstrated
that the variant viruses were capable of recognizing Bgp A as
a functional receptor (Fig. 7B). To study whether the variant
viruses were also capable of recognizing a different receptor(s)
or displayed altered binding to Bgp A, blockade experiments
were performed with BHK-MHVR cells. The blockade of
MAb CC1 completely arrested the replication of the parental
MHV-A59 in BHK-MHVR cells (.6 log units). Also, replica-
tion of the V12 and V161 variant viruses was reduced by about
4 to 5 log units compared with controls (Fig. 7B). These data
suggest that the variant viruses and MHV-A59 probably rec-
ognize a similar domain in Bgp A which is accessible to MAb
CC1 but that variant viruses probably display a greater avidity
for Bgp A, as the MAb CC1 blockade was not complete. Since
the MAb CC1 blockade reduced the number of BHK-MHVR
cells infected by variant viruses from .85 to ,2%, these data
strongly imply that variant viruses must also recognize an al-
ternative receptor(s) for entry into DBT cells as well as PDBT
cells which do not express Bgp A.
Previous studies have indicated that wild-type MHV-A59
can interact with Bgp B (mmCGM2) as a receptor for entry,
although with much less efficiency than Bgp A (17, 67). As an
alternative approach to determine whether the variant viruses
display altered recognition of BGPs, BHK-mmCGM2 cells,
which stably express Bgp B, were infected with MHV-A59,
V12, or V161. Consistent with previous findings, Bgp B was
inefficiently used as a receptor by MHV-A59, since virus titers
only approached 104 PFU/ml after 24 h of infection and virus
yields were only about 0.5 PFU per cell. Under identical con-
ditions, Bgp B was efficiently utilized as a receptor by V12 and
V161 viruses and replicated to a 3- to 4-log-higher titer than
MHV-A59 (Fig. 7C). Peak V12 and V161 virus yields reached
30 and 13 PFU per cell, respectively. By immunofluorescence
assay, the number of BHK-mmCGM2 cells infected by the
V12 and V161 viruses (66 and 49%, respectively) was signif-
icantly higher than the number of the same cells infected by
MHV-A59 (,2%). Although binding assays will be needed to
prove this hypothesis, these data strongly imply that the variant
viruses contain mutations which permit an altered, more effi-
cient interaction with the Bgp B receptor.
If MHV persistence in vitro selects for more-virulent viruses
that are capable of infecting resistant cells which express low
levels of BGP and if this is a critical element for regulating
persistence, then the majority of the persisting virus should
display this altered phenotype. To test this hypothesis, we
examined the receptor specificities of four additional variant
viruses (V42, V131, V141, and V151) isolated from persis-
tently infected cultures at 119 days postinfection. DBT 9 cells
FIG. 6. Replication of MHV-A59, V12, and V161 in PDBT 5 cells trans-
fected with Bgp A (PDBT 5 R-14 or PDBT 5 R-22 cells). Cells (2 3 105) were
infected with viruses at an MOI of 5, and samples were harvested at different
time postinfection. (A) Growth of MHV-A59, V12, and V161 in the PDBT 5
clone expressing Bgp A (PDBT 5 R-14). (B) Growth of MHV-A59 in the PDBT
5 R-14 clone and a Bgp A-negative PDBT 5 clone (PDBT 5 R-22). (C) MAb CC1
blockade in PDBT 5 R-14 cells.
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were pretreated with MAb CC1 as described above and in-
fected with the four variant viruses. As in the case of the V12
and V161 variant viruses, MAb CC1 pretreatment failed to
inhibit the replication of all other variant viruses in DBT 9 cells
(Fig. 8). Taken together, our data argue that MHV persistence
in vitro is mediated by the selection of resistant host cells that
display reduced levels of Bgp1 expression and by the subse-
quent coevolution of more-virulent variant viruses which dis-
play altered BGP receptor avidities and use an alternative
receptor(s) for entry into resistant cells.
DISCUSSION
Roles of the host cell and coevolving virus in MHV persis-
tence. The recent demonstration of persisting coronaviruses in
mouse and primate central nervous systems and in the brains
FIG. 7. Receptor specificities of variant viruses. Cultures of DBT 9 (A),
BHK-MHVR (B), and BHK-mmCGM2 (C) cells were seeded at 2 3 105 cells
per well and infected with MHV-A59, V12, and V161 at an MOI of 5 for 1 h.
The pretreatment of cells with MAb CC1 was performed as described in Mate-
rials and Methods.
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of multiple sclerosis patients has increased interest in identi-
fying the critical sites of host-virus interaction which regulate
the establishment and maintenance of coronavirus persistence
(9, 23, 44, 49). MHV-A59 produces an acute cytolytic infection
in DBT cells, yet persistent infections are readily established,
providing a reproducible model of a naturally occurring virus
infection (30, 34). In the absence of prior exposure to virus,
cloned DBT cell lines not only displayed heterogeneous levels
of Bgp1 expression but also displayed different susceptibilities
to wild-type MHV-A59 infection. This is not surprising, since a
similar variability has also been reported with other cell lines in
culture and since clonal expansion of individual cells in BHK-21
and 17CL-1 cell populations occurred during FMDV andMHV-
A59 persistence (41, 54). The generation of cell diversity may
also be favored in transformed cell lines because of their in-
herent genetic instability (46). After establishing MHV-A59
persistent cultures in 17CL-1 cells, Sawicki et al. (54) demon-
strated the emergence of resistant host cell variants at passages
97 and 402 (about 290 and 1,200 days postinfection, respec-
tively). In our studies, we have demonstrated that as early as 30
days postinfection, resistant cells which expressed little if any
Bgp A receptor protein emerged. The rapid emergence of
resistant DBT populations within 30 days postinfection, cou-
pled with the findings of resistant 17CL-1 cells at 3 years
postinfection (54), argues that host cell resistance is probably
the critical element that functions in both the establishment
and maintenance of MHV persistence in vitro. Cell resistance
is mediated at the level of entry, since transfection and expres-
sion of Bgp A in resistant cells restored a phenotype of sus-
ceptibility to wild-type infection. However, we cannot rule out
the possibility that some resistant host cells that arrest viral
infection at other stages in the growth cycle may also arise
during persistence, since other sites of virus-host interaction
may also affect MHV entry, transcription, assembly, and re-
lease (69). Since a small percentage of the DBT cell population
(;4%) survives acute MHV-A59 infection, it seems unlikely
that host cell resistance resulted from mutational processes
attributed to the virus. Rather, resistant cells were probably
selected from preexisting host cell variants present within the
cell population. In our model a small percentage (,1%) of the
cloned resistant cells (PDBT 5 cells) remained susceptible to
wild-type infection, consistent with the hypothesis that epige-
netic variation contributed to ongoing MHV persistence in
vitro (54). However, our results also reveal that the major
mechanism for MHV persistence in vitro involves not only the
selection for resistant host cells but also the selection for more-
virulent viruses.
Rapid RNA virus evolution is a hallmark of persistent in-
fections in vitro and in vivo (1, 7, 12, 32), yet it has been
suggested that MHV persistence is uncoupled from the emer-
gence of mutant viruses in vitro (43, 54). We disagree with this
hypothesis and argue that MHV persistence in DBT cells is
dependent upon the coevolution of virus. We have clearly
demonstrated that MHV-A59 persistence in DBT cells se-
lected for more-virulent variant viruses which displayed signif-
icantly increased lethality in both DBT and persistent cell
clones. It is interesting to note that variant viruses isolated
from persistently infected 17CL-1 cells also replicated more
efficiently than wild-type virus in parental as well as in persis-
tent cell clones (54), strongly suggesting that similar coevolu-
tionary mechanisms may also occur in this model. Although
the exact genotypic alterations regulating increased MHV vir-
ulence in cell culture are unclear, the variant viruses described
in this paper are the first clearly defined MHV mutants that
displayed altered receptor specificity and avidity and cell tro-
pisms in vitro. Mutations which alter binding and/or increased
avidity for Bgp A might evolve and permit infection of cells
expressing marginal levels of Bgp1. Alternatively, variant vi-
ruses might recognize a new receptor(s) for entry into resistant
cells, or both mechanisms might evolve during MHV persis-
tence in vitro. This would not be unprecedented, since entero-
tropic strains of MHV probably recognize native receptors
other than Bgp A for entry (11) and human immunodeficiency
virus recognizes at least two different receptors for entry into
cells (21, 69). Our findings are also consistent with the hypoth-
esis that neurotropic strains of MHV may either use alterna-
tive receptors for entry into the central nervous system or
display altered avidity that permits infection of central nervous
system cells which express marginal levels of Bgp receptor (70).
Although Bgp A and Bgp B clearly function as efficient
receptors for entry of variant viruses, the efficient MAb CC1
blockade in BHK-MHVR but not in DBT cells argues that
these viruses use alternative receptors for entry into DBT cells.
Although the identity of the receptor(s) is unclear, variant
viruses could interact with an unrecognized polymorphic Bgp
gene product(s) expressed in DBT cells, such as Bgp2 (45). Bgp
A is a member of the CEA immunoglobulin superfamily, which
is composed of a large number of closely related genes (63).
MAbs directed against individual CEA proteins usually cross-
react with other members in the gene family (52, 57, 63), and
sequence analysis demonstrates a high degree of protein iden-
tity among different CEA subfamilies, especially within the
IgC-like elements. Even greater degrees of homology exist
within each subfamily (63). It is plausible that the mutations in
variant viruses may not only permit recognition of polymorphic
BGP alleles (45) but also permit recognition of closely related
CEA family members to promote entry. Although less likely,
entirely unrelated proteins might also be recognized as recep-
tors for entry into resistant cells. Additional studies will be
needed to clarify whether closely related CEA proteins or
other proteins act as receptors for entry of variant viruses into
resistant cell clones.
Host resistance and the evolution of virus virulence. Among
the four types of persistent viral infections in cell culture (39),
FIG. 8. Replication of MHV-A59 and variant viruses V42, V131, V141, and
V151 in the presence of MAb CC1 in DBT 9 cells. Cultures of 23 105 cells were
pretreated with MAb CC1 for 1 h and infected with viruses at an MOI of 5.
Viruses were harvested at different time postinfection and titrated on DBT cells.
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carrier cultures are characterized by having a small proportion
of the cell population infected with virus. These infected cells
lyse, and the progeny virions infect a small number of addi-
tional cells. Carrier cultures can be cured with neutralizing
antibodies. Persistent infections by MHV as well as most other
coronaviruses resemble carrier cultures, since only small per-
centages of cells are antigen positive and cultures can be cured
of virus by the addition of neutralizing antibodies (62). Persis-
tent infections by coronaviruses, like other carrier cultures, are
also characterized by inefficient vertical transmission of virus
and are dependent upon horizontal transmission for mainte-
nance (14, 15). During persistent infection by MHV-A59 in
DBT cells, the inefficient vertical transmission of virus initially
resulted from the selection of resistant cells which expressed
little if any Bgp1 proteins, since most of receptor-positive cells
were rapidly lysed by acute MHV infection. Resistant Bgp1-
negative cells proliferated and established an alternative eco-
logical niche which formed a genetic bottleneck for the subse-
quent selection of more-virulent variant viruses that could
proliferate more efficiently in these resistant cells (Fig. 9). By
altering their receptor avidities and specificities, these more-
virulent variants provided continuous pressure for selecting
more-resistant cells in culture. As a result, the persistent in-
fection is maintained not only by epigenetic expression of Bgp1
and other putative host factors that affect virus replication (69)
but also by the coevolution of resistant cells and more-virulent
viruses in vitro. Consequently, neither cells nor viruses com-
pletely dominate in culture, ensuring dual survival.
Our data predict that extremely virulent viruses which will be
incapable of establishing a persistent infection in the original
DBT cell line will eventually emerge. Conversely, extremely
resistant host cells which cannot be infected by wild-type virus
or prevent the establishment of a persistent infection may also
emerge. In fact, resistant 17 Cl-1 cells in which parental MHV-
A59 could not establish a persistent infection did evolve, yet
persistent infections with variant viruses isolated after 1 year
postinfection were readily established in these cells (54). Since
receptors for transmissible gastroenteritis coronavirus, human
coronavirus 229E, bovine coronavirus, and human coronavirus
OC43 have been identified and persistent carrier culture in-
fections are readily established in vitro (13, 31, 33, 64, 68),
similar coevolutionary mechanisms may also mediate persis-
tence of these coronaviruses in vitro. MHV persistence has
been extensively studied with neuronal OBLA21A and primary
mixed glial cell cultures (26, 27). Although the mechanisms for
persistence in these in vitro models are unknown, initial virus
infection is associated with little if any syncytium formation
and few cells become infected with virus. The percentage of
antigen-positive cells increased with time, and fusion-negative
mutants emerged within 2 months postinfection. These viral
mutants contain alterations within a highly conserved putative
host protease cleavage site and within the fusigenic domain of
the S glycoprotein gene (26, 27). Since wild-type MHV-A59
infection in these cell cultures does not elicit cell fusion, as it
does in other cell cultures, the coevolutionary pressures likely
favored the emergence of mutant viruses which did not require
syncytium formation for efficient transmission and replication.
Through 119 days postinfection, we have not identified variant
viruses with altered fusigenic capacities, although coevolving
host ecologies might select such mutants at later times in per-
sistence.
While many theorists have suggested that host-parasite sys-
tems coevolve from increased parasitism to commensalism and
reduced virulence, others have argued that natural selection
may favor increased pathogen virulence in systems in which
host pathology clearly favors increased pathogen transmission
(35). While some pathogens may become less virulent, many
examples point to the contrary proposition of pathogens evolv-
ing virulent countermeasures to increasing host resistance. Not
surprisingly, evidence suggests that many human viruses have
become less virulent than they were in the past, which is at-
tributed primarily to the emergence of host resistance to in-
fection (35). Host resistance to infection is a complex process
governed by numerous genes, relatively few of which have been
identified. Genes affecting host resistance to malaria, cholera,
and tuberculosis infections have been reported (24, 25, 40, 58,
59), and the humanMx gene product (MXA) protects cultured
cells against infection with influenza virus and vesicular stoma-
titis virus (48). Major histocompatibility complex polymor-
phisms clearly contribute to increased resistance or suscepti-
bility to different virus infections (3, 5). In our in vitro model,
coevolutionary mechanisms have apparently selected for more-
virulent viruses that did not evolve toward commensalism but
rather evolved increased virulence as a means of countering
increased host cell resistance in vitro. Infection by these highly
evolved variant viruses in unselected host cell populations re-
sulted in tremendous lethality and cell death, akin to the dev-
astation caused by smallpox and measles viruses at the organ-
ism level following introduction into indigenous, naive New
World populations (5). The introduction of highly virulent
myxoma viruses into rabbits in Australia resulted in the rapid
selection for more-resistant rabbits and the coselection for
FIG. 9. Mechanism of MHV persistence in vitro. Highly cytolytic MHV in-
fection results in the death of susceptible cell populations, selecting for resistant
cells which express little if any BGP receptor. The proliferation of resistant cells
forms a genetic bottleneck which selects for the coevolution of more-virulent
variant viruses. The variant viruses display increased avidity for BGP receptors
and/or recognize new receptors for entry into resistant cells. The emergence of
new variant viruses results in additional rounds of selection for new populations
of resistant cells and subsequent coevolution of variant viruses, ensuring MHV
persistence and the coexistence of the host cells and virus.
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attenuated variant viruses which had high levels of transmissi-
bility in a given rabbit population. Also seen was the selection
for more-virulent viruses in the rabbit populations that had the
highest innate resistance (22). It seems possible that coevolving
host resistance and virus virulence over many generations in
geographically isolated populations may contribute to the emer-
gence of extremely virulent pathogens following transmission
into naive external populations.
Coevolution in a biological system requires an interdepen-
dence between the modes of evolution of both entities (20, 35,
36). Coevolution has been hypothesized to occur during reo-
virus persistence in vitro, in which variant viruses which repli-
cated more efficiently than wild-type viruses in parental and
cured persistent cell clones were selected (15). While similar
observations have been made for persistently infected cultures
of FMDV and lymphotropic minute virus of mice (12, 50), the
molecular mechanisms that modulate virus-host coevolution
have not been elucidated. We have identified at least two sites
of virus-host interaction which coevolve with increasing host
cell resistance and likely modulate virus virulence in vitro. The
59-UTR mutation in some variant viruses increased translation
and expression of the MHV polymerase genes in cell culture,
thereby enhancing virus gene expression and replication (10).
A second mutation site likely involves genetic changes which
remodel the S glycoprotein gene so that the variant viruses can
interact more efficiently with BGP receptors and/or recognize
an alternative receptor(s) for entry, thereby circumventing in-
creased host resistance. These data suggest that MHV persis-
tence may represent a unique biological model to identify the
genetic determinants of virus-host interaction that regulate
host resistance and virus virulence at the cellular level. This
model also may reflect important sites of virus-host coevolu-
tion in vivo, since the resistant SJL/J mouse expresses a poly-
morphic Bgp B receptor that is poorly utilized by MHV-JHM
and MHV-A59. MHV-3 however, replicates efficiently and
produces disease in the SJL/J mouse (8, 69). The variant vi-
ruses isolated in this study will likely allow us to identify high-
affinity receptor binding sites which regulate virus entry, tissue
tropism, and pathogenesis in cell culture and in animals.
ACKNOWLEDGMENTS
We thank Robert E. Johnson and Nancy L. Davis for helpful dis-
cussions and Boyd Young, Jr., and Erlina Siraqusa for excellent tech-
nical assistance.
This study was supported by a research grant from the National
Institutes of Health (AI 23964) and a fellowship to W.C. from the U.S.
Public Health Service (5 T32 A107151-16). This work was performed
during the tenure of an established investigator award from the Amer-
ican Heart Association (89-0193) (to R.S.B.).
REFERENCES
1. Ahmed, R., C. S. Hahn, T. Somasundaram, L. Villarette, M. Matloubian,
and J. H. Strauss. 1991. Molecular basis of organ-specific selection of viral
variants during chronic infection. J. Virol. 65:4242–4247.
2. Ahmed, R., and J. G. Stevens. 1990. Viral persistence, p. 241–265. In B. N.
Fields and D. M. Knipe (ed.), Virology. Raven Press, New York.
3. Apple, R. J., H. A. Erlich, W. Klitz, M. M. Manos, T. M. Becker, and C. M.
Wheeler. 1994. HLA DR-DQ associations with cervical carcinoma show
papillomavirus-type specificity. Nature Genet. 6:157–162.
4. Baybutt, H. N., H. Wege, M. J. Carter, and V. Ter Meulen. 1984. Adaptation
of coronavirus JHM to persistent infection of murine Sac(2) cells. J. Gen.
Virol. 65:915–924.
5. Black, F. L. 1992. Why did they die? Science 258:1739–1740.
6. Borzakian, S., T. Couderc, Y. Barbier, G. Attal, I. Pelletier, and F. Colbere-
Garapin. 1992. Persistent poliovirus infection: infection establishment and
maintenance involve distinct mechanisms. Virology 186:398–408.
7. Borzakian, S., I. Pelletier, V. Calvez, and F. Colbere-Garapin. 1993. Precise
missense and silent point mutations are fixed in the genomes of poliovirus
mutants from persistently infected cells. J. Virol. 67:2914–2917.
8. Boyle, J. F., D. G. Weismiller, and K. V. Holmes. 1987. Genetic resistance to
mouse hepatitis virus correlates with absence of virus-binding activity on
target tissues. J. Virol. 61:185–189.
9. Burks, J. S., B. L. Devald, L. D. Jakovsky, and J. C. Gerdes. 1980. Two
coronaviruses isolated from central nervous system tissue of two multiple
sclerosis patients. Science 209:933–934.
10. Chen, W., and R. S. Baric. 1995. Function of a 59-end genomic RNA muta-
tion that evolves during persistent mouse hepatitis virus infection in vitro. J.
Virol. 69:7529–7540.
11. Compton, S. R. 1994. Enterotropic strains of mouse coronavirus differ in
their use of murine carcinoembryonic antigen-related glycoprotein recep-
tors. Virology 203:197–201.
12. de la Torre, J. C., E. Martı́nez-Salas, J. Diez, A. Villaverde, F. Gebauer, E.
Rocha, M. Dávila, and E. Domingo. 1988. Coevolution of cells and viruses in
a persistent infection of foot-and-mouth disease virus in cell culture. J. Virol.
62:2050–2058.
13. Delmas, B., J. Gelfi, R. L’Haridon, L. K. Vogel, H. Sjostrom, O. Noren, and
H. Laude. 1992. Aminopeptidase N is a major receptor for the enteropatho-
genic coronavirus TGEV. Nature (London) 357:417–420.
14. Dermody, T. S., J. D. Chappell, J. G. Hofler, W. Kramp, and K. L. Tyler.
1995. Eradication of persistent reovirus infection from a B-cell hybridoma.
Virology 212:272–276.
15. Dermody, T. S., M. L. Nibert, D. Wetzel, X. Tong, and B. N. Fields. 1993.
Cells and viruses with mutations affecting viral entry are selected during
persistent infections of L cells with mammalian reoviruses. J. Virol. 67:2055–
2063.
16. Dveksler, G. S., A. A. Basile, C. B. Cardellichio, and K. V. Holmes. 1995.
Mouse hepatitis virus receptor activities of an MHVR/mph chimera and
MHVR mutants lacking N-linked glycosylation of the N-terminal domain. J.
Virol. 69:543–546.
17. Dveksler, G. S., C. W. Dieffenbach, C. B. Cardellichio, K. McCuaig, M. N.
Pensiero, G.-S. Jiang, N. Beauchemin, and K. V. Holmes. 1993. Several
members of the mouse carcinoembryonic antigen-related glycoprotein fam-
ily are functional receptors for the coronavirus mouse hepatitis virus-A59. J.
Virol. 67:1–8.
18. Dveksler, G. S., M. N. Pensiero, C. B. Cardellichio, R. K. Williams, G.-S.
Jiang, K. V. Holmes, and C. W. Dieffenbach. 1991. Cloning of the mouse
hepatitis virus (MHV) receptor: expression in human and hamster cell lines
confers susceptibility to MHV. J. Virol. 65:6881–6891.
19. Dveksler, G. S., M. N. Pensiero, C. W. Dieffenbach, C. B. Cardellichio, A. A.
Basile, P. E. Ella, and K. V. Holmes. 1993. Mouse hepatitis virus strain A59
and blocking antireceptor monoclonal antibody bind to the N-terminal do-
main of cellular receptor. Proc. Natl. Acad. Sci. USA 90:1716–1720.
20. Ewald, P. W. 1993. The evolution of virulence. Sci. Am. 4:86–93.
21. Fantini, J., D. G. Cook, N. Nathanson, S. L. Spitalnik, and F. Gonzalez-
Scarano. 1993. Infection of colonic epithelial cell lines by type 1 human
immunodeficiency virus is associated with cell surface expression of galac-
tosylceramide, a potential alternative gp120 receptor. Proc. Natl. Acad. Sci.
USA 90:2700–2704.
22. Fenner, F., and P. J. Kerr. 1994. Evolution of the poxviruses, including the
coevolution of virus and host in myxomatosis, p. 273–292. In S. S. Morse
(ed.), The evolutionary biology of viruses. Raven Press, Ltd., New York.
23. Fleming, J. O., J. J. Houtman, H. Alaca, H. C. Hinze, D. McKenzie, J. Aiken,
T. Bleasdale, and S. Baker. 1994. Persistence of viral RNA in the central
nervous system of mice inoculated with MHV-4, p. 327–332. InH. Laude and
F. J. Vautherot (ed.), Coronaviruses. Plenum Press, New York.
24. Friedman, M. J. 1978. Erythrocytic mechanism of sickle-cell resistance to
malaria. Proc. Natl. Acad. Sci. USA 75:1994–1997.
25. Gabriel, S. E., K. N. Brigman, B. H. Koller, R. C. Boucher, and M. J. Stutts.
1994. Cystic fibrosis heterozygote resistance to cholera toxin in the cystic
fibrosis mouse model. Science 266:107–109.
26. Gallagher, T. M., C. Escarmis, and M. J. Buchmeier. 1991. Alteration of the
pH dependence of coronavirus-induced cell fusion: effect of mutations in the
spike glycoprotein. J. Virol. 65:1916–1928.
27. Gombold, J. L., S. T. Thingley, and S. R. Weiss. 1993. Fusion-negative
mutants of mouse hepatitis virus A59 contain a mutation in the spike protein
cleavage signal. J. Virol. 67:4504–4512.
28. Hingley, S. T., J. L. Gombold, E. Lavi, and S. R. Weiss. 1994. MHV-A59
fusion mutants are attenuated and display altered hepatotropism. Virology
200:1–10.
29. Hirano, N., K. Fujiwara, S. Hino, and M. Matumoto. 1974. Replication and
plaque formation of mouse hepatitis virus (MHV-2) in mouse cell line DBT
culture. Arch. Gesamte Virusforsch. 44:298–302.
30. Hirano, N., N. Goto, S. Makino, and K. Fujiwara. 1981. Persistent infection
with mouse hepatitis virus JHM strain in DBT cell culture, p. 301–308. In V.
ter Meulen, S. Siddell, and H. Wege (ed.), Biochemistry and biology of
coronaviruses. Plenum Press, New York.
31. Hofmann, M. A., R.-Y. Chang, S. Ku, and D. A. Brian. 1993. Leader-mRNA
junction sequences are unique for each subgenomic mRNA species in the
bovine coronavirus and remain so throughout persistent infection. Virology
196:163–171.
32. Hofmann, M. A., S. D. Senanayake, and D. A. Brian. 1993. A translation-
attenuating intraleader open reading frame is selected on coronavirus mRNAs
VOL. 70, 1996 COEVOLUTION OF HOST RESISTANCE AND VIRUS VIRULENCE 3959
  
during persistent infection. Proc. Natl. Acad. Sci. USA 90:11733–11737.
33. Hofmann, M. A., P. B. Sethna, and D. A. Brian. 1990. Bovine coronavirus
mRNA replication continues throughout persistent infection in cell culture.
J. Virol. 64:4108–4114.
34. Holmes, K. V., and J. N. Behnke. 1981. Evolution of a coronavirus during
persistent infection in vitro, p. 287–299. In V. ter Meulen, S. Siddell, and H.
Wege (ed.), Biochemistry and biology of coronaviruses. Plenum Press, New
York.
35. Johnson, R. B. 1986. Human disease and the evolution of pathogen viru-
lence. J. Theor. Biol. 122:19–24.
36. Kilbourne, E. D. 1994. Host determination of virus evolution: a variable
tautology, p. 253–271. In S. S. Morse (ed.), The evolutionary biology of
viruses. Raven Press, Ltd., New York.
37. Knobler, R. L., P. W. Lampert, and M. B. A. Oldstone. 1982. Virus persis-
tence and recurring demyelination produced by a temperature-sensitive mu-
tant of MHV-4. Nature (London) 298:279–280.
38. Kumanishi, T. 1967. Brain tumors induced with Rous sarcoma virus,
Schmidt-Ruppin strain. 1. Introduction of brain tumors in adult mice with
Rous chicken sarcoma cells. Jpn. J. Exp. Med. 37:461–474.
39. Mahy, B. W. J. 1985. Strategies of viral persistence. Br. Med. Bull. 41:50–55.
40. Malo, D., and E. Skamene. 1994. Genetic control of host resistance to
infection. Trends Genet. 10:365–371.
41. Martin Hernandez, A. M., E. C. Carrillo, N. Sevilla, and E. Domingo. 1994.
Rapid cell variation can determine the establishment of a persistent viral
infection. Proc. Natl. Acad. Sci. USA 91:3705–3709.
42. McCuaig, K., M. Rosenberg, P. Nedellec, C. Turbide, and N. Beauchemin.
1993. Expression of the Bgp gene and characterization of mouse colon biliary
glycoprotein isoforms. Gene 127:173–183.
43. Mizzen, L., S. Cheley, M. Rao, R. Wolf, and R. Anderson. 1983. Fusion
resistance and decreased infectability as major host cell determinants of
coronavirus persistence. Virology 128:407–417.
44. Murray, R. S., G.-Y. Cai, K. Hoel, J.-Y. Zhang, K. F. Soike, and G. F.
Cabirac. 1992. Coronavirus infects and causes demyelination in primate
central nervous system. Virology 188:274–284.
45. Nedellec, P., G. S. Dveksler, E. Daniels, C. Turbide, B. Chow, A. A. Basile,
K. V. Holmes, and N. Beauchemin. 1994. Bgp2, a new member of the
carcinoembryonic antigen-related gene family, encodes an alternative recep-
tor for mouse hepatitis viruses. J. Virol. 68:4525–4537.
46. Nicolson, G. L. 1987. Tumor cell instability, diversification, and progression
to the metastatic phenotype: from oncogene to oncofetal expression. Cancer
Res. 47:1473–1487.
47. Pachuk, C., P. J. Bredenbeek, P. W. Zoltick, W. J. M. Spaan, and S. R. Weiss.
1989. Molecular cloning of the gene encoding the putative polymerase of
mouse hepatitis coronavirus, strain A59. Virology 171:141–148.
48. Pavlovic, J., O. Haller, and P. Staeheli. 1992. Human and mouse Mx proteins
inhibit different steps of the influenza virus multiplication cycle. J. Virol.
66:2564–2569.
49. Perlman, S., G. Jacobsen, L. A. Olson, and A. Afifi. 1990. Identification of the
spinal cord as a major site of persistence during chronic infection with a
murine coronavirus. Virology 175:418–426.
50. Ron, D., and J. Tal. 1985. Coevolution of cells and virus as a mechanism for
the persistence of lymphotropic minute virus of mice in L cells. J. Virol.
55:424–430.
51. Rosner, B. 1990. Fundamentals of biostatistics, p. 336–342. PWS-KENT
Publishing Co., Boston.
52. Rudert, F., A. M. Saunders, S. Rebstock, J. A. Thompson, and W. Zimmer-
mann. 1992. Characterization of murine carcinoembryonic antigen gene
family members. Mamm. Genome 3:262–273.
53. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a
laboratory manual, 2nd ed., p. 14.2–14.4. Cold Spring Harbor Laboratory
Press, Cold Spring Harbor, N.Y.
54. Sawicki, S. G., J.-H. Lu, and K. V. Holmes. 1995. Persistent infection of
cultured cells with mouse hepatitis virus (MHV) results from the epigenetic
expression of the MHV receptor. J. Virol. 69:5535–5543.
55. Schaad, M. C., and R. S. Baric. 1993. Evidence for new transcriptional units
encoded at the 39 end of the mouse hepatitis virus genome. Virology 196:
190–198.
56. Schaad, M. C., S. A. Stohlman, J. Egbert, K. Lum, K.-S. Fu, T. J. Wei, and
R. S. Baric. 1990. Genetics of mouse hepatitis virus transcription: identifi-
cation of cistrons which may function in positive and negative strand RNA
synthesis. Virology 177:634–645.
57. Shively, J. E., and J. D. Beatty. 1985. CEA-related antigens: molecular
biology and clinical significance. Crit. Rev. Oncol. Hematol. 2:355–399.
58. Skamene, E. 1991. Population and molecular genetics of susceptibility to
tuberculosis. Clin. Invest. Med. 14:160–166.
59. Stead, W. W. 1992. Genetics and resistance to tuberculosis: could resistance
be enhanced by genetic engineering? Ann. Intern. Med. 116:937–941.
60. Stohlman, S. A., A. Y. Sakaguchi, and L. P. Weiner. 1979. Characterization
of the cold-sensitive hepatitis virus mutants rescued from latently infected
cells by cell fusion. Virology 98:448–455.
61. Stohlman, S. A., A. Y. Sakaguchi, and L. P. Weiner. 1979. Rescue of a
positive-stranded RNA virus from antigen-negative neuroblastoma cells.
Life Sci. 24:1029–1036.
62. Stohlman, S. A., and L. P. Weiner. 1978. Stability of neurotropic mouse
hepatitis virus (JHM) strain during chronic infection of neuroblastoma cells.
Arch. Virol. 57:53–61.
63. Thompson, J. A., F. Grunert, and W. Zimmermann. 1991. The carcinoem-
bryonic antigen gene family: molecular biology and clinical perspectives. J.
Clin. Lab. Anal. 5:63–83.
64. Vlasak, R., W. Luytjes, W. J. M. Spaan, and P. Palese. 1988. Human and
bovine coronaviruses recognize sialic acid-containing receptor similar to
those of influenza C virus. Proc. Natl. Acad. Sci. USA 85:4526–4529.
65. Wang, K.-S., R. J. Kuhn, E. G. Strauss, S. Ou, and J. H. Strauss. 1992.
High-affinity laminin receptor is a receptor for Sindbis virus in mammalian
cells. J. Virol. 66:4992–5001.
66. Weiss, R. A. 1993. Cellular receptors and viral glycoproteins involved in
retrovirus entry, p. 1–108. In J. A. Levy (ed.), The Retroviridae. Plenum
Press, New York.
67. Williams, R. K., G.-S. Jiang, S. W. Snyder, M. F. Frana, and K. V. Holmes.
1990. Purification of the 110-kilodalton glycoprotein receptor for mouse
hepatitis virus (MHV)-A59 from mouse liver and identification of a non-
functional, homologous protein in MHV-resistant SJL/J mice. J. Virol. 64:
3817–3823.
68. Yeager, C. L., R. A. Ashmun, R. K. Williams, C. B. Cardellichio, L. H.
Shapiro, A. T. Look, and K. V. Holmes. 1992. Human aminopeptidase N is
a receptor for human coronavirus 229E. Nature (London) 357:420–422.
69. Yokomori, K., M. Asanaka, S. A. Stohlman, and M. M. C. Lai. 1993. A spike
protein-dependent cellular factor other than the viral receptor is required for
mouse hepatitis virus entry. Virology 196:45–56.
70. Yokomori, K., and M. M. C. Lai. 1992. Mouse hepatitis virus utilizes two
carcinoembryonic antigens as alternative receptors. J. Virol. 66:6194–6199.
3960 CHEN AND BARIC J. VIROL.
